版本:
中国

BRIEF-Bioverativ announces FDA acceptance of investigational new drug application for BIVV001

June 12 Bioverativ Inc

* Bioverativ announces FDA acceptance of investigational new drug application for BIVV001 to treat hemophilia A

* Look forward to commencing our phase 1/2A clinical trial later this year

* On track to initiate a phase 1/2A clinical trial in second half of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐